NASDAQ:MDGL Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $279.79 -6.43 (-2.25%) (As of 02/3/2023 09:04 PM ET) Add Compare Share Share Today's Range$278.98▼$288.0050-Day Range$58.39▼$306.7552-Week Range$57.15▼$315.45Volume289,400 shsAverage Volume355,030 shsMarket Capitalization$4.78 billionP/E RatioN/ADividend YieldN/APrice Target$286.45 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Madrigal Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside2.4% Upside$286.45 Price TargetShort InterestHealthy7.47% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.59Based on 3 Articles This WeekInsider TradingSelling Shares$20.41 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($16.66) to ($16.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector286th out of 1,025 stocksPharmaceutical Preparations Industry134th out of 498 stocks 2.4 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $286.45, Madrigal Pharmaceuticals has a forecasted upside of 2.4% from its current price of $279.79.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.47% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently decreased by 12.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 2.5 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Madrigal Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 24 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,414,070.00 in company stock.Percentage Held by Insiders29.71% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.98% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to decrease in the coming year, from ($16.66) to ($16.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -17.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -17.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 24.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Madrigal Pharmaceuticals (NASDAQ:MDGL) StockMadrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.Read More Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Stock News HeadlinesJanuary 30, 2023 | finance.yahoo.comMadrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To ProfitJanuary 29, 2023 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Hold at StockNews.comFebruary 6, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 20, 2023 | finance.yahoo.comIntercept's (ICPT) NDA for NASH Treatment Accepted By FDAJanuary 14, 2023 | seekingalpha.comMDGL Madrigal Pharmaceuticals, Inc.January 9, 2023 | msn.comHere's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 YearsJanuary 7, 2023 | finance.yahoo.comTop Picks 2023- Madrigal Pharmaceuticals MDGLJanuary 6, 2023 | finance.yahoo.comMadrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver FibrosisFebruary 6, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 3, 2023 | benzinga.comThis Is What Whales Are Betting On Madrigal PharmaceuticalsJanuary 3, 2023 | bizjournals.comWith stock up 350%, Madrigal secures more than $300M to advance NASH drug candidateDecember 26, 2022 | seekingalpha.comMadrigal Pharmaceuticals Setting The StandardDecember 26, 2022 | finance.yahoo.comThis Stock That Tripled in 2022 Could Rocket Even Higher in 2023December 23, 2022 | finance.yahoo.comWhy Madrigal Pharmaceuticals Was a Top Stock This WeekDecember 22, 2022 | finance.yahoo.comBiotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & MoreDecember 21, 2022 | seekingalpha.comMadrigal: Next Steps After 'Wow' Data In NASHDecember 21, 2022 | seekingalpha.comMadrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 SuccessDecember 21, 2022 | finance.yahoo.comMeet the Biotech Stock That Jumped Over 260% in One DayDecember 20, 2022 | msn.comPeering Into Madrigal Pharmaceuticals's Recent Short InterestDecember 20, 2022 | msn.com$1000 Invested In Madrigal Pharmaceuticals 5 Years Ago Would Be Worth This Much TodayDecember 20, 2022 | markets.businessinsider.comAnalyst Ratings for Madrigal PharmaceuticalsDecember 20, 2022 | msn.comHere's How An Options Trader Made $5.5 Million In One DayDecember 20, 2022 | finance.yahoo.comEstimating The Fair Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)December 19, 2022 | msn.comMadrigal closes up 268% on positive late-stage results for NASH candidate resmetiromDecember 19, 2022 | finance.yahoo.comMadrigal's Successful Late-Stage Trial Draws Options BullsDecember 19, 2022 | cnbc.comOptions Action: Action in MDGLDecember 19, 2022 | barrons.comMadrigal Pharmaceuticals Stock More Than Doubles on ‘NASH’ BreakthroughSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Company Calendar Last Earnings11/04/2021Today2/05/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees71Year Founded2011Price Target and Rating Average Stock Price Forecast$286.45 High Stock Price Forecast$390.00 Low Stock Price Forecast$151.00 Forecasted Upside/Downside+2.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($16.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-241,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-251.34% Return on Assets-125.82% Debt Debt-to-Equity Ratio4.59 Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.47 per share Price / Book24.39Miscellaneous Outstanding Shares17,100,000Free Float12,022,000Market Cap$4.78 billion OptionableOptionable Beta-0.52 Social Links Key ExecutivesPaul A. FriedmanChairman, President & Chief Executive OfficerAlex G. HowarthChief Financial OfficerRebecca A. TaubDirector & Chief Medical OfficerStephen DodgeSenior Vice President-Global Medical AffairsBrian J. LynchSenior Vice President & General CounselKey CompetitorsAlkermesNASDAQ:ALKSIonis PharmaceuticalsNASDAQ:IONSAmicus TherapeuticsNASDAQ:FOLDIronwood PharmaceuticalsNASDAQ:IRWDDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsEmerald Advisers LLCBought 12,988 shares on 2/3/2023Ownership: 0.076%Emerald Mutual Fund Advisers TrustBought 10,469 shares on 2/3/2023Ownership: 0.061%D.A. Davidson & CO.Bought 720 shares on 2/3/2023Ownership: 0.004%AtonRa PartnersSold 1,543 shares on 2/2/2023Ownership: 0.033%Profund Advisors LLCBought 1,133 shares on 2/2/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions MDGL Stock - Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price forecast for 2023? 10 Wall Street analysts have issued 12-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $151.00 to $390.00. On average, they anticipate the company's share price to reach $286.45 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts. How have MDGL shares performed in 2023? Madrigal Pharmaceuticals' stock was trading at $290.25 at the beginning of the year. Since then, MDGL shares have decreased by 3.6% and is now trading at $279.79. View the best growth stocks for 2023 here. When is Madrigal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our MDGL earnings forecast. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.79) earnings per share for the quarter, topping the consensus estimate of ($3.87) by $0.08. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). What is Madrigal Pharmaceuticals' stock symbol? Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL." Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.73%), Hennion & Walsh Asset Management Inc. (0.27%), New York State Common Retirement Fund (0.13%), Emerald Advisers LLC (0.08%), Emerald Mutual Fund Advisers Trust (0.06%) and XR Securities LLC (0.00%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Madrigal Pharmaceuticals' stock price today? One share of MDGL stock can currently be purchased for approximately $279.79. How much money does Madrigal Pharmaceuticals make? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.78 billion. The biopharmaceutical company earns $-241,850,000.00 in net income (profit) each year or ($16.03) on an earnings per share basis. How can I contact Madrigal Pharmaceuticals? Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228. This page (NASDAQ:MDGL) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.